HTG Molecular Diagnostics Inc (STU:65H)

€ 0.242 0 (0%) Market Cap: 1,000.00 Enterprise Value: -2.44 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

HTG Molecular Diagnostics Inc Key Opinion Leader (KOL) “The Role of RNA Profiling in Drug Discovery and Analysis” - Corporate Call Transcript
Dec 13, 2022
Q2 2022 HTG Molecular Diagnostics Inc Earnings Call Transcript
Aug 11, 2022

€13.06 (+0.93%)

Earnings
HTG Molecular Diagnostics Inc Host a Key Opinion Leader (KOL) Webinar Transcript
Jul 27, 2022
Q1 2022 HTG Molecular Diagnostics Inc Earnings Call Transcript
May 12, 2022

€6.54 (-20.84%)

Earnings
Q4 2021 HTG Molecular Diagnostics Inc Earnings Call Transcript
Mar 29, 2022

€17.16

Earnings
Q3 2021 HTG Molecular Diagnostics Inc Earnings Call Transcript
Nov 10, 2021

€51.12 (-1.84%)

Earnings
Q2 2021 HTG Molecular Diagnostics Inc Earnings Call Transcript
Aug 12, 2021

€59.04 (-4.47%)

Earnings
Q1 2021 HTG Molecular Diagnostics Inc Earnings Call Transcript
May 13, 2021

€36.72 (-6.13%)

Earnings
Q4 2020 HTG Molecular Diagnostics Inc Earnings Call Transcript
Mar 25, 2021

€54.24 (-2.16%)

Earnings
Q3 2020 HTG Molecular Diagnostics Inc Earnings Call Transcript
Nov 10, 2020

€53.28 (+8.82%)

Earnings
Q2 2020 HTG Molecular Diagnostics Inc Earnings Call Transcript
Aug 11, 2020

€95.4 (+2.91%)

Earnings
Q1 2020 HTG Molecular Diagnostics Inc Earnings Call Transcript
May 13, 2020

€64.44 (+0.56%)

Earnings
Q4 2019 HTG Molecular Diagnostics Inc Earnings Call Transcript
Mar 25, 2020

€53.28 (-1.99%)

Earnings
HTG Molecular Diagnostics, Inc. - Special Call Transcript
Dec 13, 2019
Q3 2019 HTG Molecular Diagnostics Inc Earnings Call Transcript
Nov 12, 2019

€126 (-3.45%)

Earnings
HTG Molecular Diagnostics, Inc. - Special Call Transcript
Oct 29, 2019
Q2 2019 HTG Molecular Diagnostics Inc Earnings Call Transcript
Aug 06, 2019

€209.88 (+1.99%)

Earnings
Q1 2019 HTG Molecular Diagnostics Inc Earnings Call Transcript
May 09, 2019

€388.89 (-0.78%)

Earnings
Q4 2018 HTG Molecular Diagnostics Inc Earnings Call Transcript
Mar 07, 2019

€405 (+0.90%)

Earnings

Q3 2020 HTG Molecular Diagnostics Inc Earnings Call Transcript

Nov 10, 2020 / 09:30PM GMT

Release Date Price: €53.28 (+8.82%)

Transcript 10-Q8-K

Operator

Greetings, and welcome to the HTG Molecular Diagnostics, Inc. Third Quarter 2020 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Paul Arndt with LifeSci Advisors. Thank you. You may begin.

Paul J. Arndt

LifeSci Advisors, LLC - Head of IR and MD, Communications

Thank you, operator. Earlier today, HTG released its financial results for the third quarter ended September 30, 2020.

Before we begin the call, let me remind you that the company's remarks include forward-looking statements within the meaning of the federal securities laws, including statements regarding increasing use of RNA-based biomarkers; expected growth in the molecular profiling market; anticipated growth in the company's RUO profiling business and related revenue; expectations regarding biopharma programs and collaborations; product development and commercialization activities; and the impact of and potential recovery from the ongoing COVID-19 pandemic.

These forward-looking

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.